Overcoming Cancer Multidrug Resistance by Codelivery of Doxorubicin and Verapamil with Hydrogel Nanoparticles

The efficacy of chemotherapy is often inhibited by multidrug resistance (MDR). A highly engineerable hydrogel nanoparticle (NP) serves as a carrier for the optimal codelivery to tumor cells of the chemodrug, doxorubicin (Dox) and the chemosensitizer, verapamil (Vera), aiming at alleviating tumor MDR...

Full description

Saved in:
Bibliographic Details
Published in:Macromolecular bioscience 2014-08, Vol.14 (8), p.1106-1115
Main Authors: Qin, Ming, Lee, Yong-Eun Koo, Ray, Aniruddha, Kopelman, Raoul
Format: Article
Language:English
Subjects:
Analysis of Variance
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - pharmacology
cancer therapy
Cell Line, Tumor
Chemotherapy
Doxorubicin
Doxorubicin - administration & dosage
Drug delivery systems
Drug Delivery Systems - methods
Drug Resistance, Multiple - drug effects
Drug Resistance, Neoplasm - drug effects
Drug therapy
Drugs
Humans
hydrogel nanoparticles
Hydrogel, Polyethylene Glycol Dimethacrylate - therapeutic use
Hydrogels
In vitro testing
Medical research
Microscopy, Confocal
multidrug resistance
Nanoparticles
Nanoparticles - therapeutic use
Nanostructure
Neoplasms - drug therapy
Tumors
verapamil
Verapamil - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy of chemotherapy is often inhibited by multidrug resistance (MDR). A highly engineerable hydrogel nanoparticle (NP) serves as a carrier for the optimal codelivery to tumor cells of the chemodrug, doxorubicin (Dox) and the chemosensitizer, verapamil (Vera), aiming at alleviating tumor MDR. The hydrogel NPs are prepared via the copolymerization of acrylamide and 2‐carboxyethyl acrylate. Dox and Vera are post‐loaded into the respective NPs, with drug loading around 7.7 wt% and 8.0 wt%, respectively. The codelivery of Dox‐NPs and Vera‐NPs increases the intracellular accumulation of Dox, and significantly enhances the cell killing ability of Dox with respect to NCI/ADR‐RES cells in vitro. These findings suggest that such codelivery nanoplatforms provide a promising route for overcoming tumor MDR. A new kind of hydrogel nanoparticles is developed as a delivery vehicle for codelivery of doxorubicin, an anti‐cancer drug (affects DNA), and verapamil, a chemosensitizer (blocks efflux pump), to tumor cells, aiming at overcoming multidrug resistance.
ISSN:1616-5187
1616-5195
DOI:10.1002/mabi.201400035